New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
07:41 EDTSNYSanofi R&D focused on biology of disease, WSJ reports
Dr. Elias Zerhouni, a former director of the U.S. National Institutes of Health, and now head of R&D at Sanofi (SNY) is attempting to shift to an earlier stage of research and development, and boost the number and quality of the company's drug discoveries. He has recruited about 20 new R&D leaders to help Sanofi become better at understanding how diseases work and how to target them. "We're investing a lot more upstream in understanding human-disease biology," he says. "We're extremely good at toolmaking," he added, referring to the formulation of new pills and shots, "but not very good at understanding the biology" of disease.Reference Link
News For SNY From The Last 14 Days
Check below for free stories on SNY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2014
12:19 EDTSNYOn The Fly: Midday Wrap
Subscribe for More Information
11:48 EDTSNYSanofi and Regeneron co-host a conference call
Subscribe for More Information
10:40 EDTSNYBiotechs rise after InterMune acquired by Roche
Subscribe for More Information
August 22, 2014
12:39 EDTSNYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
August 21, 2014
05:42 EDTSNYIllumina announces strategic partnership with AstraZeneca, Sanofi, Janssen
Illumina (ILMN) announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation sequencing, or NGS,-based oncology test system. The system will be used for clinical trials of targeted cancer therapies with a goal of developing and commercializing a multi-gene panel for therapeutic selection, resulting in a more comprehensive tool for precision medicine. Initial strategic partners include AstraZeneca (AZN), Janssen Biotech, a Johnson & Johnson (JNJ) company, and Sanofi (SNY). Illumina is working with the strategic partners to develop assays that detect and measure multiple variants simultaneously to support partners’ clinical trials, with the objectives of securing regulatory agency approvals and test commercialization. In parallel, Illumina is working with key thought leaders to set standards for NGS-based assays in routine clinical oncology practice, as well as to define regulatory frameworks to enable this new testing paradigm. Together, Illumina and its strategic partners aim to transition from single-analyte companion diagnostics to panel-based assays that select for “companion therapeutics.”
August 19, 2014
16:46 EDTSNYFDA approves Genzyme Cerdelga capsules
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use